, Sophie Ma? ?ga, 2004.
, , vol.1, p.3
, Christelle Dousset, vol.1, p.5
, , 2004.
, , p.6
, Agnès Moreau-Aubry, vol.7, p.3
, Martine Amiot, vol.1, p.4
, Catherine Pellat-Deceunynck, vol.1
,
, Nantes F, vol.44000
, Centre d'investigation Clinique
, Myelomax SAS
, Histocompatibilit eet d'Immunog en etique, Etablissement Franc¸ais du Sang Pays de la Loire
Check your cultures! A list of cross-contaminated or misidentified cell lines, Int J Cancer, vol.127, pp.1-8, 2010. ,
Cell line cross-contamination initiative: An interactive reference database of STR profiles covering common cancer cell lines, Int J Cancer, vol.126, pp.303-304, 2010. ,
Nomenclature for factors of the HLA system, Tissue Antigens, vol.75, pp.291-455, 2010. ,
An update to HLA nomenclature, Bone Marrow Transplant, vol.45, pp.846-848, 2010. ,
Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells, Clin Cancer Res, vol.5, pp.705-709, 1999. ,
HLA class I and II genotype of the NCI-60 cell lines, J Transl Med, vol.3, p.11, 2005. ,
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, pp.574-582, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00550232
Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK, Cell Death Dis, vol.5, p.1389, 2014. ,
ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents, Clin Cancer Res, vol.17, pp.5973-5981, 2011. ,
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy, Haematologica, vol.91, pp.1234-1240, 2006. ,
Report of the european myeloma network on multiparametric flow cytometry in multiple myeloma and related disorders, Haematologica, vol.93, pp.431-438, 2008. ,